# Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct07416994/  
OnCo record `nct07416994` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing YL202 in non-small-cell lung cancer, now recruiting.

## Summary

Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer is a phase 3 interventional study registered as NCT07416994, led by MediLink Therapeutics (Suzhou), and recruiting on the registry. Official title: A Multicenter, Randomised, Open-label, Phase III Study to Compare the Efficacy and Safety of YL202 and Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer. Planned enrolment is 440 participants (estimated). The study started in 2026-03-18 and primary completion is expected in 2028-08-31. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT07416994
- Phase: 3
- Setting: A Multicenter, Randomized, Open-label, Phase III Study to Compare the Efficacy and Safety of YL202 and Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer
- Sponsor: MediLink Therapeutics (Suzhou)
- Enrolled: 440

## Sources

- ClinicalTrials.gov NCT07416994: https://clinicaltrials.gov/study/NCT07416994

## Connected records

- cancers: [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [YL202](https://onco.cc/drugs/yl202/)
- companies: [MediLink Therapeutics](https://onco.cc/companies/medilink/)

---
JSON: https://onco.cc/api/v1/entities/nct07416994.json